|1.||Fujii, Masayuki: 2 articles (01/2008 - 09/2005)|
|2.||Reed, J C: 2 articles (04/2006 - 08/2001)|
|3.||Neurath, M F: 2 articles (10/2001 - 02/2001)|
|4.||Morales-Medina, Julio Cesar: 1 article (01/2014)|
|5.||Iannitti, Tommaso: 1 article (01/2014)|
|6.||Palmieri, Beniamino: 1 article (01/2014)|
|7.||Ahmed, Khalil: 1 article (10/2011)|
|8.||Unger, Gretchen M: 1 article (10/2011)|
|9.||Korman, Vicci L: 1 article (10/2011)|
|10.||Slaton, Joel W: 1 article (10/2011)|
04/01/1999 - "Phosphorothioate oligonucleotides can be effectively induced into ganglion cells, and specifically into cells in choroidal neovascularization. "
06/01/2002 - "To evaluate the efficacy of the gene transfer of a double-stranded phosphorothioate oligonucleotides (ODNs), called a "decoy", against the NF-kappaB binding site into cells of an experimentally-induced choroidal neovascularization. "
04/01/1999 - "The purpose of this study was to determine whether the inactivated hemagglutinating virus of Japan (HVJ)-liposome method can induce phosphorothioate oligonucleotides effectively into an experimentally-induced choroidal neovascularization of rats. "
04/01/1999 - "Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system."
04/01/1999 - "Phosphorothioate oligonucleotides were effectively induced into ganglion cells and into the cells of the choroidal neovascularization induced by laser photocoagulation. "
07/01/2002 - "The use of phosphorothioate oligonucleotides as antisense agents has shown promising results in various preclinical cancer models. "
01/15/1997 - "To exclude the possibility that, in other tumor cell lines, the autocrine growth factor may interact with its receptor within the cell, the ability of antisense phosphorothioate oligonucleotides to inhibit the growth of the tumor cells was tested. "
02/23/1996 - "Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides."
12/01/1991 - "Hence, pharmacokinetic considerations are not likely to be limiting factors in anti-cancer drug design with phosphorothioate oligonucleotides."
10/01/2011 - "We previously reported that direct injection of antisense (AS) CK2α phosphorothioate oligonucleotides (PTO) into xenograft prostate tumors in mice significantly reduced tumor size. "
12/01/1997 - "Specific downregulation of p65 by administration of antisense phosphorothioate oligonucleotides to mice with experimental colitis abrogated clinical and histological signs of mucosal inflammation. "
09/01/1996 - "Local administration of p65 antisense phosphorothioate oligonucleotides abrogated clinical and histological signs of colitis and was more effective in treating TNBS-induced colitis than single or daily administration of glucocorticoids. "
09/01/1996 - "Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice."
01/01/2011 - "WT1 antisense phosphorothioate oligonucleotides could both inhibit the proliferation and induce the apoptosis in SKOV3 ovarin carcinoma cell lines. "
08/28/2001 - "In contrast, the combination of Ad.mda-7 with antisense phosphorothioate oligonucleotides, which target the K-ras oncogene (a gene that is mutated in 85 to 95% of pancreatic carcinomas), induces a dramatic suppression in growth and a decrease in cell viability by induction of apoptosis. "
06/01/1998 - "A human breast carcinoma cell line, BT474, which overexpresses the HER2/neu oncogene was exposed to AS, sense (S), or scrambled antisense (SC) phosphorothioate oligonucleotides in tissue culture. "
07/01/2004 - "In this study, we demonstrated the possibility of modulating the hTERT splicing pattern in DU145 human prostate carcinoma cells through the use of 2'-O-methyl-RNA phosphorothioate oligonucleotides targeting the splicing site located between intron 5 and exon 6 in the hTERT pre-mRNA. "
01/01/2011 - "WT1 antisense phosphorothioate oligonucleotides did not only inhibit cell proliferation, arrest cell cycle at G0-G1 checkpoint and induce apoptosis in SKOV3 ovarian carcinoma cells, but also downregulated WT1 mRNA and protein expression, which contributed to the apoptosis (p < 0.05). "
06/01/2003 - "To study the effects of bcl-2 antisense phosphorothioate oligonucleotides (ASPO) on suppression of HL-60 cell growth in SCID mice and to investigate the feasibility of purging leukemia cells plus bcl-2 ASPO used in vitro. "
11/16/1990 - "Addition of phosphorothioate oligonucleotides that contained the octamer consensus to Jurkat T leukemia cells inhibited interleukin-2 (IL-2) secretion to a degree similar to that observed with a mutated octamer site in the IL-2 enhancer. "
01/01/2008 - "As a result, antisense oligonucleotides conjugated with NLS could inhibit human telomerase in human leukemia cells much more strongly than phosphorothioate oligonucleotides."
09/21/2005 - "As a result, antisense oligonucleotides conjugated with NLS could inhibit human telomerase in human leukemia cells much more strongly than phosphorothioate oligonucleotides."
|1.||NF-kappa B (NF-kB)
|3.||Messenger RNA (mRNA)
|5.||DNA (Deoxyribonucleic Acid)
|7.||Matrix Metalloproteinase 7 (Matrilysin)
|8.||Transforming Growth Factor beta (TGF-beta)
|9.||RNA Precursors (Precursor, mRNA)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Tissue Therapy (Cell Therapy)